On the public citation graph

Immunogenicity and Reactogenicity of Modified Vaccinia Ankara Pre-Exposure Vaccination Against Mpox According to Previous Smallpox Vaccine Exposure

https://doi.org/10.2139/ssrn.4572849
0 signed · 30 inferred · view as graph

Inferred edges come from two machine sources: sweeps of open repository metadata (mostly SSRN and Zenodo), and a bulk OpenAlex citation snapshot. Every row below is labelled with the one it came from. Neither is a complete citation index — absence here is not evidence of absence.

Is this your work? Sign in with ORCID and put your name on the claims that are yours.
Claim with ORCID
Reference health. See whether every reference in this work resolves to a known work and none has been retracted — and get a dated CiteStamped badge you can embed.
See reference health

What this work says

Outgoing claims: the papers this work cites, builds on, or argues with.

inferredcites →https://doi.org/10.1001/jama.2023.7683openalex-extracted
Short-term Adverse Events Following Immunization With Modified Vaccinia Ankara-Bavarian Nordic (MVA-BN) Vaccine for Mpox
inferredcites →https://doi.org/10.1002/jmv.28778openalex-extracted
Characterization of immune response against monkeypox virus in cohorts of infected patients, historic and newly vaccinated subjects
inferredcites →https://doi.org/10.1016/bs.aivir.2016.07.001openalex-extracted
Modified Vaccinia Virus Ankara
inferredcites →https://doi.org/10.1016/j.isci.2023.106102openalex-extracted
Kinetics of viral DNA in body fluids and antibody response in patients with acute Monkeypox virus infection
inferredcites →https://doi.org/10.1016/j.vaccine.2015.06.075openalex-extracted
Comparison of lyophilized versus liquid modified vaccinia Ankara (MVA) formulations and subcutaneous versus intradermal routes of administration in healthy vaccinia-naïve subjects
inferredcites →https://doi.org/10.1016/j.vaccine.2020.01.058openalex-extracted
A randomized phase II trial to compare safety and immunogenicity of the MVA-BN smallpox vaccine at various doses in adults with a history of AIDS
inferredcites →https://doi.org/10.1016/s0140-6736(22)01436-2openalex-extracted
Clinical presentation and virological assessment of confirmed human monkeypox virus cases in Spain: a prospective observational cohort study
inferredcites →https://doi.org/10.1016/s0140-6736(23)00588-3openalex-extracted
Mpox neglect and the smallpox niche: a problem for Africa, a problem for the world
inferredcites →https://doi.org/10.1016/s1473-3099(22)00513-8openalex-extracted
Monkeypox virus isolation from a semen sample collected in the early phase of infection in a patient with prolonged seminal viral shedding
inferredcites →https://doi.org/10.1016/s1473-3099(23)00057-9openalex-extracted
Effectiveness of one dose of MVA–BN smallpox vaccine against mpox in England using the case-coverage method: an observational study
inferredcites →https://doi.org/10.1016/s1473-3099(23)00115-9openalex-extracted
Can a single dose of Modified Vaccinia Ankara-Bavarian Nordic vaccine protect against mpox?
inferredcites →https://doi.org/10.1016/s1473-3099(23)00369-9openalex-extracted
Progress in the evaluation of modified vaccinia Ankara vaccine against mpox
inferredcites →https://doi.org/10.1038/nm917openalex-extracted
Duration of antiviral immunity after smallpox vaccination
inferredcites →https://doi.org/10.1038/s41577-022-00775-4openalex-extracted
Monkeypox: disease epidemiology, host immunity and clinical interventions
inferredcites →https://doi.org/10.1038/s41591-022-02090-wopenalex-extracted
Low levels of monkeypox virus-neutralizing antibodies after MVA-BN vaccination in healthy individuals
inferredcites →https://doi.org/10.1038/s41591-023-02229-3openalex-extracted
Real-world effectiveness of a single dose of mpox vaccine in males
inferredcites →https://doi.org/10.1056/nejmc2215846openalex-extracted
Erythema and Induration after Mpox (JYNNEOS) Vaccination Revisited
inferredcites →https://doi.org/10.1056/nejmoa1817307openalex-extracted
Phase 3 Efficacy Trial of Modified Vaccinia Ankara as a Vaccine against Smallpox
inferredcites →https://doi.org/10.1056/nejmoa2207323openalex-extracted
Monkeypox Virus Infection in Humans across 16 Countries — April–June 2022
inferredcites →https://doi.org/10.1056/nejmoa2215201openalex-extracted
Vaccine Effectiveness of JYNNEOS against Mpox Disease in the United States
inferredcites →https://doi.org/10.1093/infdis/jiac455openalex-extracted
One- and Two-Dose Vaccinations With Modified Vaccinia Ankara-Bavarian Nordic Induce Durable B-Cell Memory Responses Comparable to Replicating Smallpox Vaccines
inferredcites →https://doi.org/10.1093/infdis/jis753openalex-extracted
Safety, Immunogenicity, and Surrogate Markers of Clinical Efficacy for Modified Vaccinia Ankara as a Smallpox Vaccine in HIV-Infected Subjects
inferredcites →https://doi.org/10.1093/ofid/ofv040openalex-extracted
Safety and Immunogenicity of Modified Vaccinia Ankara-Bavarian Nordic Smallpox Vaccine in Vaccinia-Naive and Experienced Human Immunodeficiency Virus-Infected Individuals: An Open-Label, Controlled Clinical Phase II Trial
inferredcites →https://doi.org/10.1093/ofid/ofv183openalex-extracted
Safety and Immunogenicity of Modified Vaccinia Ankara-Bavarian Nordic Smallpox Vaccine in Vaccinia-Naive and Experienced Human Immunodeficiency Virus-Infected Individuals: An Open-Label, Controlled Clinical Phase II Trial
inferredcites →https://doi.org/10.1128/jvi.03481-12openalex-extracted
Assessment of the Protective Effect of Imvamune and Acam2000 Vaccines against Aerosolized Monkeypox Virus in Cynomolgus Macaques
inferredcites →https://doi.org/10.1371/journal.pone.0157335openalex-extracted
A Randomized, Double-Blind, Placebo-Controlled Phase II Trial Investigating the Safety and Immunogenicity of Modified Vaccinia Ankara Smallpox Vaccine (MVA-BN®) in 56-80-Year-Old Subjects
inferredcites →https://doi.org/10.2807/1560-7917.es.2022.27.22.2200421openalex-extracted
Epidemiological, clinical and virological characteristics of four cases of monkeypox support transmission through sexual contact, Italy, May 2022
inferredcites →https://doi.org/10.2807/1560-7917.es.2023.28.12.2200772openalex-extracted
Mpox outbreak in the Netherlands, 2022: public health response, characteristics of the first 1,000 cases and protection of the first-generation smallpox vaccine

What points at this work

Incoming claims: where this work appears in other papers’ reference lists and arguments.

inferred← citeshttps://doi.org/10.1038/s43856-025-01340-5openalex-snapshot
Behavior change and infection induced immunity led to the decline of the 2022 Mpox outbreak in Berlin
inferred← citeshttps://doi.org/10.1186/s12879-025-12172-yopenalex-snapshot
Pre-exposure vaccination in the high-risk population is crucial in controlling mpox resurgence in Canada
Editorial review for independent work. ICSAC — the Institute for Complexity Science and Advanced Computing — runs a structured editorial panel for researchers publishing outside journals, and publishes on CiteStamp rails. Submission is free and goes through ORCID: icsacinstitute.org/submit.